SCHEMBL3204506

SCHEMBL3204506

c1ccc(CC(Nc2ccccc2)c2ccccc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.72
CYP3A4 P08684 1/20 0.72
CYP2D6 P10635 1/20 0.72
CYP2C9 P11712 1/20 0.72
CYP2C19 P33261 1/20 0.72
HTT P42858 2/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
KDM4E B2RXH2 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
ALDH1A1 P00352 1/20 0.50
NCOA1 Q15788 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
MAPT P10636 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KCNN3 Q9UGI6 1/20 0.47
NPBWR1 P48145 1/20 0.44
MCHR1 Q99705 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27747558 0.83 ALDH1A1 (0.54) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6932504 0.81 L3MBTL1 (0.57) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL11765847 0.80 CYP3A4 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10936752 0.78 HTT (0.58) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL13621571 0.77 TAAR1 (0.57) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7093029 0.77 TAAR1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2096552 0.77 HTT (0.51) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL17985414 0.77 SCN1A (0.49) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL18065741 0.77 HTT (0.51) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1541692 0.77 TAAR1 (0.57) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299284-B2 Frustrated lewis pair compositions STEPHAN CONSULTING CORPORATION (CA) 2012-10-30 US claimed
US-8642812-B2 Frustrated Lewis pair compositions STEPHAN CONSULTING CORPORATION (CA) 2014-02-04 US disclosed
US-8642812-B2 Frustrated Lewis pair compositions STEPHAN CONSULTING CORPORATION (CA) 2014-02-04 US disclosed
US-8642812-B2 Frustrated Lewis pair compositions STEPHAN CONSULTING CORPORATION (CA) 2014-02-04 US disclosed
US-20130018207-A1 Frustrated Lewis Pair Compositions STEPHAN CONSULTING CORPORATION (CA) 2013-01-17 US disclosed
US-20130018207-A1 Frustrated Lewis Pair Compositions STEPHAN CONSULTING CORPORATION (CA) 2013-01-17 US disclosed
US-20130018207-A1 Frustrated Lewis Pair Compositions STEPHAN CONSULTING CORPORATION (CA) 2013-01-17 US disclosed
US-8299284-B2 Frustrated lewis pair compositions STEPHAN CONSULTING CORPORATION (CA) 2012-10-30 US disclosed
US-8299284-B2 Frustrated lewis pair compositions STEPHAN CONSULTING CORPORATION (CA) 2012-10-30 US disclosed
US-20100048949-A1 HYDROGEN SPLITTING COMPOSITION STEPHAN CONSULTING CORPORATION (CA) 2010-02-25 US disclosed
US-20100048949-A1 HYDROGEN SPLITTING COMPOSITION STEPHAN CONSULTING CORPORATION (CA) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018207-A1 Frustrated Lewis Pair Compositions LPAR3, SSTR3, LPAR1 CYP1A2 2332/4885CYP3A4 3790/4885CYP2D6 2994/4885
US-20100048949-A1 HYDROGEN SPLITTING COMPOSITION SSTR3, FFAR3, SSTR1 CYP1A2 968/4885CYP3A4 2339/4885CYP2D6 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.